The ongoing ALNEO clinical trial is also to evaluate the efficacy and safety of alectinib as neoadjuvant therapy in surgically resectable stage III ALK-positive NSCLC (Leonetti et al., 2021). The gene discussed is ALK; the disease is non-small cell lung carcinoma.